

Isocitrate Dehydrogenase (IDH) inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2018

<https://marketpublishers.com/r/I5747DFA985EN.html>

Date: October 2018

Pages: 59

Price: US\$ 3,000.00 (Single User License)

ID: I5747DFA985EN

Abstracts

This report can be delivered to the clients within 24 hours

'Isocitrate Dehydrogenase (IDH) inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2018', report provides comprehensive insights about marketed and pipeline drugs across this mechanism of action. The report provides the detailed analysis of 8+ products along with 5+ companies involved. Agios Pharmaceuticals and Novartis are developing therapeutic drugs in the higher phase and Agios has been granted Orphan and Fast-track Designation both from FDA.

Products covered by Phase

Phase III, Phase II and Phase I

Pre-clinical and Discovery

Overview of pipeline development activities for Isocitrate Dehydrogenase (IDH) inhibitors

Pipeline analysis of 8+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.

Therapeutic segmentation of products for Isocitrate Dehydrogenase (IDH) inhibitors

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism of action.

METHODOLOGY

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SCOPE

The report provides competitive pipeline landscape of Isocitrate Dehydrogenase (IDH) inhibitors

The report provides the marketed drugs information including its sales, development activities and details of patent expiry

The report provides the insight of current and future market for Isocitrate Dehydrogenase (IDH) inhibitors

The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

Coverage of the Isocitrate Dehydrogenase (IDH) inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

The report reviews key players involved in the therapeutics development for Isocitrate Dehydrogenase (IDH) inhibitors and also provide company profiling

Pipeline products coverage based on various stages of development ranging from late stage till discovery stage

Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

REASONS TO BUY

Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage

Establish a comprehensive understanding of the current pipeline scenario across Isocitrate Dehydrogenase (IDH) inhibitors to formulate effective R&D strategies

Assess challenges and opportunities that influence Isocitrate Dehydrogenase (IDH) inhibitors R&D

Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine

Devise corrective measures for pipeline projects by understanding Isocitrate Dehydrogenase (IDH) inhibitors pipeline depth and focus of target therapeutics

Developing strategic initiatives to support your drug development activities

Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Isocitrate Dehydrogenase (IDH) inhibitors to enhance and expand business potential and scope

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs

Gaining a full picture of the Competitive Landscape for Evidence based Decisions

Contents

Executive Summary
IDH Targets
Overview
Competitive Landscape
Marketed Product
Idhifa: Celgene Corporation
Product Description
Research and Development
Pipeline Activity
Product Development Activities
Idhifa Sales
Pipeline Therapeutics
Comparative Analysis
Late Stage Products
Comparative Analysis
AG-120: Agios Pharmaceuticals
Product Description
Research and Development
Product Development Activities
AG-120 (Ivosidenib) Sales
(The list continues)
Mid-Stage Products
Comparative Analysis
Early Stage Products
Comparative Analysis
Pre-clinical and Discovery Stage Products
Comparative Analysis
Therapeutic Assessment
Institutional Product
Dormant Products
Comparative Analysis
Market Drivers and Barriers
Appendix

List Of Tables

LIST OF TABLES

Table 1: Total Products for Isocitrate dehydrogenase Inhibitors

Table 2: Late Stage Products (Phase III)

Table 3: Mid Stage Products (Phase II)

Table 4: Early Stage Products (Phase I)

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Monotherapy Products

Table 7: Assessment by Route of Administration

Table 8: Assessment by Stage and Route of Administration

Table 9: Assessment by Molecule Type

Table 10: Assessment by Stage and Molecule Type

Table 11: Dormant Products

List Of Figures

LIST OF FIGURES

- Figure 1: Mechanism of IDH Inhibitors
- Figure 2: Idhifa Forecasted Sales
- Figure 3: Total Products for Isocitrate dehydrogenase Inhibitors
- Figure 4: Late Stage Products (Phase III)
- Figure 5: AG-120 (Ivosidenib) Forecasted Sales (2018-2025)
- Figure 6: Mid Stage Products (Phase II)
- Figure 7: Early Stage Products (Phase I)
- Figure 8: Pre-clinical & Discovery Stage Products
- Figure 9: Assessment by Monotherapy Products
- Figure 10: Assessment by Route of Administration
- Figure 11: Assessment by Stage and Route of Administration
- Figure 12: Assessment by Molecule Type
- Figure 13: Assessment by Stage and Molecule Type
- Figure 14: Dormant Products

I would like to order

Product name: Isocitrate Dehydrogenase (IDH) inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2018

Product link: <https://marketpublishers.com/r/I5747DFA985EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I5747DFA985EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

